We were all excited by
1) Mouse preclinical results
2) “Retina in a dish” results
3) Rabbit eye results
4) NHP eye results
5) First-in-human administration
for RP11 treatment.
The market couldn’t have given a fat rat’s arse.
I truly don’t believe any other announcements of proposed new treatments for this or that body part will elicit any different reaction. How could it?
The only thing that will shift this thing is when multiples of US$150,000 start hitting the till.
In my opinion.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-17
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $583.2M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 12.5¢ | $45.90K | 360.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 497798 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 201892 | 2 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |